The Gold Standard Paradox: 

Manual vs Algorithm Assisted Scoring in
Breast Cancer Diagnostics 


Watch the recording:

Digital vs Manual Scoring for Breast Pathology Webinar


Thursday 18th November 2021

17:00 - 17:50 (AEDT)


Image analysis algorithms are a hot topic when it comes to digital pathology - but what are the benefits and challenges in using such innovations and how is that compared to the traditional routine manual scoring under the microscope? Let this live head-to-head session give us an idea!


Join two of Australia’s leading Breast Pathologists, A/Prof Nirmala Pathmanathan of the Western Sydney Breast Cancer Institute and Dr Cameron Snell of Mater Pathology, for this side-by-side battle of HER2 Dual ISH scoring: manual vs algorithm assisted.


Who should attend:

Pathologists, lab scientists, researchers


Reasons to attend:

  • Real-time concordance of manual HER2 Dual ISH Scoring vs Digitally assisted scoring.
  • Hear from key opinion leaders the benefits and challenges of algorithm assisted scoring.


A/Prof Nirmala Pathmanathan

Associate Professor Nirmala Pathmanathan is an anatomical pathologist at Douglas Hanly Moir with expertise in breast diseases. She is also the Service Director of the Westmead Breast Cancer Institute in Sydney, a comprehensive multidisciplinary breast cancer program covering Western Sydney. Assoc. Prof. Pathmanathan worked from 2002 to 2016 as a Senior Staff Specialist in the Department of Tissue Pathology and Diagnostic Oncology, Pathology West. She is also the Designated/Lead Pathologist and the Director for the BreastScreen Program in Sydney West, a Clinical Associate Professor with the University of Sydney and Conjoint Associate Professor with the University of Western Sydney.


Dr Cameron Snell

Dr Cameron Snell BMedSc MBBS (Melb.) DPhil (Oxon.) FRCPA is an Anatomical Pathologist with Mater Pathology in Brisbane. He is involved in teaching and research with Mater Research and as an honorary senior lecturer at the University of Queensland. In 2010, he was awarded the Oxford Nuffield Fellowship, which allowed him to develop novel diagnostic assays and complete his PhD in tumour hypoxia. He leads the Cancer Pathology Research Group, which collaborates widely with cancer research groups in breast, melanoma, lung and gynaecological cancers. He completed his fellowship in 2014 having been awarded the Eddie Hirst memorial prize for pathological sciences.


Dr Richie Lazaro

Regional Pathologist APAC, Roche






17:00 - 17:05

(5 minutes)

Welcome and Introduction

Dr Richie Lazaro

17:05 - 17:15

(10 minutes)

Introduction from Speakers




17:15 - 17:30

(15 minutes)



Recorded Scoring

Each pathologist will score as many of the five cases provided as possible in 10 minutes


A/Prof Nirmala Pathmanathan to be scoring manually


Dr Cameron scoring with uPath Algorithm assistance

17:30 - 17:45

(15 minutes)

Q&A Session

17:45 17:50

(5 minutes)


Dr Richie Lazaro


Thursday 18th November 2021


17:00 - 17:55 (AEDT)

16:30 - 17:15 (Adelaide)

16:00 - 16:55 (Brisbane)

15:30 - 16:15 (Darwin)

14:00 - 14:55 (Perth)

19:00 - 16:55 (New Zealand)

11:00 - 11:55 (Karachi)
11:30 - 12:15 (Delhi)
13:00 - 13:55 (Bangkok / Ho Chi Minh / Jakarta)
14:00 - 14:55 (Hong Kong / Kuala Lumpur / Singapore)
15:00 - 15:55 (Seoul / Tokyo)


DISCLAIMER. This website contains information on products that are targeted to a wide range of audiences. Please be aware that Roche Diagnostics Australia Pty Limited does not take any responsibility for accessing that information that may not comply with any legal process, regulation, registration, or usage in the country of your origin. Please also be aware that the information on this website should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.


Visit Roche Diagnostics Australia


© 2021 Roche Diagnostics


Roche Diagnostics Australia Pty Limited
ABN 29 003 001 205
2 Julius Avenue
North Ryde NSW 2113 Australia
Phone: 02 9860 2222

Privacy policy | Legal statement